AP02 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Trial Timeline
Jan 1, 2026 → Jun 1, 2027
NCT ID
NCT07194382About AP02 + Placebo
AP02 + Placebo is a phase 2 stage product being developed by Avalyn Pharmaceuticals for Idiopathic Pulmonary Fibrosis (IPF). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07194382. Target conditions include Idiopathic Pulmonary Fibrosis (IPF).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07194382 | Phase 2 | Recruiting |
Competing Products
20 competing products in Idiopathic Pulmonary Fibrosis (IPF)